胸腺肽辅助治疗小儿支气管哮喘的疗效及其对患儿T细胞亚群的影响

Clinical efficacy of thymic peptide in adjuvant treatment of bronchial asthma in children and the impact on T-lymphocyte subtypes

目的探讨胸腺肽辅助治疗小儿支气管哮喘的疗效及其对患儿T细胞亚群的影响。方法将我院小儿支气管哮喘患儿92例随机分为对照组与观察组,每组46例,对照组应用常规治疗,观察组在此基础上联合胸腺肽辅助治疗,治疗后观察比较两组患儿临床疗效、治疗前后T细胞亚群变化。结果治疗后观察组临床有效率为86.96%,明显优于对照组(71.74%),观察组患儿的CD3、CD4、CD8、CD4/CD8值均明显优于对照组,其差异具有统计学意义(P<0.05)。结论胸腺肽辅助治疗小儿支气管哮喘能够明显改善患儿的生存质量,其临床疗效确切,值得临床推广。

Objective To investigate the efficacy of thymic peptide in adjuvant treatment of bronchial asthma in children, and to analyze the impact of thymic peptide on T-lymphocyte subtypes. Methods Ninety-two patients were randomly divided into the observation group and the control group, with 46 patients in each group. The control group was given conventional therapy, while the observation group received thymic peptide on the basis of the control group. The efficacy and the changes of T-lymphocyte subtypes were compared between the two groups after treatment. Results After treatment, the effective rate was 86.96% of the observation group, significantly higher than 71.74% of the control group （P〈0.05）. The CD3 , CD4 , CD8 , CD4 /CD8 score in the observation group was significantly lower than those in the control group （P〈0.05）. Conclusion Thymic peptide is safe and effective for adjuvant treatment of bronchial asthma in children, which is worthy to be promoted in clinical practice.